Baseline characteristics of the study population
| Number of patients | 44 |
| Demographics | |
| Age (years, mean (SD)) | 52.9 (10.5) |
| 0–20 | 0 (0%) |
| 21–40 | 4 (9.1%) |
| 41–60 | 29 (65.9%) |
| 60+ | 10 (22.7%) |
| Missing | 1 (2.3%) |
| Female (n, %) | 24 (54.5%) |
| Body mass index (mean (SD)) | 30.4 (4.4) |
| ACQ-7 score (mean (SD)) | 3.2 (1.2) |
| AQLQ (mean (SD)) | 3.8 (1.3) |
| Asthma history/treatment | |
| Exacerbations in prior year (median (IQR)) | 5.5 (2.5, 8.0) |
| 0 | 2 (4.5%) |
| 1 | 5 (11.4%) |
| 2–3 | 8 (18.2%) |
| 4–6 | 17 (38.6%) |
| 7–10 | 5 (11.4%) |
| 11+ | 7 (15.9%) |
| Hospitalisations in prior year (median (IQR)) | 0.0 (0.0, 1.0) |
| 0 | 23 (52.3%) |
| 1 | 11 (25.0%) |
| 2–3 | 8 (18.2%) |
| 4+ | 2 (4.5%) |
| Immunotherapy ever (n, %) | 3 (6.8%) |
| Intubated ever (n, %) | 4 (9.1%) |
| Maintenance OCS dose (median, IQR) | 10 (10, 20) |
| BDP equivalent ICS dose (median, IQR) | 2000 (2000, 2000) |
| Lung function | |
| FEV1 (L, mean (SD)) | 1.91 (0.54) |
| % FEV1 predicted (mean (SD)) | 62.4 (16.8) |
| FVC (L, mean (SD)) | 3.01 (0.71) |
| % FVC predicted (mean (SD)) | 76.9 (15.2) |
| Type-2 biomarkers | |
| Blood eosinophils (cells/µl, median (IQR)) | 200 (120,360) |
| Serum periostin (ng/mL,median (IQR)) | 49.4 (39.3, 56.3) |
| FeNO (ppb, median (IQR)) | 47.5 (18.0, 66.0) |
| IGE (IU/mL, median (IQR)) | 101 (22,255) |
| Type-2 cytokines in serum | |
| IL-5 concentration (pg/mL, median (IQR)) | 0.32 (0.13, 0.69) |
| IL-13 concentration (pg/mL, median (IQR)) | 0.46 (0.21, 0.75) |
Data are shown as median (IQR), mean (SD) or n (%) as appropriate.
AQLQ, asthma quality of life questionnaire; BDP, beclometasone dipropionate; ICS, inhaled corticosteroid; IGE, immunoglobulin E; OCS, oral corticosteroid.